Infect Chemother.  2009 Aug;41(4):230-232. 10.3947/ic.2009.41.4.230.

Primary Anti-retroviral Resistance in Treatment-naive HIV-infected Patients: A Korean HIV/AIDS Cohort Study

• Song JY
• Lee JS
• Jung HW
• Choi HJ
• Lee JS
• Lee J
• Eom JS
• Cheong HJ
• Jung MH
• Kim WJ

• KMID: 1473667
• DOI: http://doi.org/10.3947/ic.2009.41.4.230

Abstract

Primary anti-retroviral resistance is considered one of the major problems of HIV treatment. Contrary to reports from western countries, prior Korean studies have reported a relatively low primary resistance rate (less than 5%). Based on Korean HIV/AIDS cohort data, we estimated the primary resistance rate among treatment-naive HIV-infected patients. According to the results, the primary resistance rate was higher (8.8%) than reported previously in Korean studies. However, the major PI mutation was not found.

Keyword

HIV; Antiretroviral therapy; Drug resistance

MeSH Terms

Cohort Studies
Drug Resistance
HIV
Humans

Reference

1. Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill MJ, Harris R, Justice A, Hayden A, Lampe F, Mocroft A, Mugavero MJ, Staszewski S, Wasmuth JC, van Sighem A, Kitahata M, Guest J, Egger M, May M. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008. 372:293–299.

2. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M. HIV-1 drug resistance in newly infected individuals. JAMA. 1999. 282:1135–1141.

3. Briones C, Pérez-Olmeda M, Rodríguez C, del Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr. 2001. 26:145–150.

4. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 2008. 10:67–84.

5. Payne BA, Nsutebu EF, Hunter ER, Olarinde O, Collini P, Dunbar JA, Basta MS, Elston JW, Schmid ML, Thaker H, Chadwick DR. Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother. 2008. 62:464–468.

6. Janin N, Sopheak N, Regis MP, Olivier M, Sim KL, Frederic A, Martine P, Marie-Laure C, Ahidjo A, Eric N. Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-naive patients in Cambodia. AIDS Res Hum Retroviruses. 2009. 25:543–545.

7. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the Drug Resistance Mutations in HIV-1. Top HIV Med. 2008. 16:138–145.

8. Korean Centers for Disease Control and Prevention. Anti-retroviral Drug Resistance in Korean HIV/AIDS patients. Public Health Weekly Report. 2008. 1:497–500.

9. Kim SR, Rheu EK, Seol YM, Cha DH, Lee SJ, Yoon YK, Park SM, Kim HH, Rheu HS, Ahn SC, Lee SH, Kwak IS, Cho GJ. Antiretroviral drug resistance among drug-naive HIV-1 infected patients. Korean J Med. 2007. 73:243–250.

10. Bang JI, Song KH, Kim SH, Cho JH, Park WB, Park SW, Kim HB, Kim NJ, Oh MD, Choe KW. Prevalence of primary antiretroviral resistance: trends in Korea. AIDS Res Hum Retroviruses. 2008. 24:83–85.

11. Oh MD. HIV drug resistance in treatment-naive HIV patients. Korean J Med. 2007. 73:235–236.

12. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JA. A. 2008. 300:555–570.